Advertisement

Topics

Auspherix Limited (UK) Company Profile

15:07 EDT 20th June 2019 | BioPortfolio

Auspherix Ltd has discovered a brand new class of antibacterials with a unique profile and novel mechanism of action that could overcome rising problems of resistance to current antibiotics. Its compound series show activity against a broad range of multidrug resistant (MDR) important Gram-negative and Gram-positive bacterial infections, with profiles consistent with their use as antibacterial drugs for a number of indications with high unmet need and large market potential.


News Articles [37 Associated News Articles listed on BioPortfolio]

Auspherix: Meeting the urgent need for new antibiotics

Auspherix is an early-stage anti-infectives company offering new hope in the battle against antibiotic resistant bacteria. By developing a new class of antibiotics the Company will strengthen the exis...

VINTAGE PEN PIERRE CARDIN SIGMA – ALDRICH ADVERTISING LIMITED PRESENTATION BOX

EUR 7.31 (0 Bids)End Date: Wednesday Jun-19-2019 23:33:29 ISTBid now | Add to watch list Biotech365 : VINTAGE PEN PIERRE CARDIN SIGMA – ALDRICH ADVERTISING LIMITED PRESENTATION BOX BioMarke...

Fagron NV: Disclosure of received notification

Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 11 April 2019 - 7:00am CET Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major sharehold...

Quotient Limited to Participate in the Jefferies 2019 Healthcare Conference

JERSEY, Channel Islands, May 21, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s Chief Financial Officer, Chri...

Quotient Limited Receives European CE Mark for its Initial IH Microarray

JERSEY, Channel Islands, May 01, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announce...

Quotient Limited Announces Proposed Underwritten Offering of Ordinary Shares

JERSEY, Channel Islands, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the Company intends to commence an ...

Quotient Limited Announces Pricing of Underwritten Offering of Ordinary Shares

JERSEY, Channel Islands, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the pricing of its previously annou...

Quotient Limited Announces Initial MosaiQ™ SDS Verification and Validation Data

JERSEY, Channel Islands, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported positive Verification and Validation...

Drugs and Medications [33 Associated Drugs and Medications listed on BioPortfolio]

Adenosine [wockhardt limited]

Adenosine Injection, USP FOR RAPID BOLUS INTRAVENOUS USE

Felodipine [wockhardt limited]

Felodipine Extended-Release Tablets, USP Rx only

Ranitidine [wockhardt limited]

Ranitidine Syrup (Ranitidine Oral Solution, USP)

Risperidone [wockhardt limited]

These highlights do not include all the information needed to use risperidone oral solution safely and effectively. See full prescribing information for risperidone oral solution. Risperidone Oral Sol...

Amlodipine besylate [wockhardt limited]

These highlights do not include all the information needed to use amlodipine besylate tablets safely and effectively. See full prescribing information for amlodipine besylate tablets. Amlodipine Besyl...

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

THE UROLOGY MATCH PROCESS AND THE LIMITED VALUE OF POST-INTERVIEW COMMUNICATION FOR PROGRAM DIRECTORS.

To understand the urology Match process from the perspective of residency program directors, with a particular focus on the role of post-interview communication. Recent surveys of urology applicants r...

Clinical Trials [0 Results]

None

Companies [89 Associated Companies listed on BioPortfolio]

Auspherix Pty Ltd

Auspherix Pty Ltd is an early-stage anti-infectives company developing novel antibiotics to treat resistant bacterial diseases. It was spun out from the ithree institute at the Un...

Auspherix Limited

Auspherix Ltd has discovered a brand new class of antibacterials with a unique profile and novel mechanism of action that could overcome rising problems of resistance to current a...

Auspherix Limited (UK)

Auspherix Ltd has discovered a brand new class of antibacterials with a unique profile and novel mechanism of action that could overcome rising problems of resistance to current a...

Microsulis Medical Limited

Founded in 1997, Microsulis Medical Limited is a UK-based medical device company that exploits specialist intellectual property in medical microwave design to create therapeutic d...

Immunocore Limited

Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located ...

More Information about "Auspherix Limited (UK)" on BioPortfolio

We have published hundreds of Auspherix Limited (UK) news stories on BioPortfolio along with dozens of Auspherix Limited (UK) Clinical Trials and PubMed Articles about Auspherix Limited (UK) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Auspherix Limited (UK) Companies in our database. You can also find out about relevant Auspherix Limited (UK) Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record